Active Biotech: Interim report January – March 2017

Apr 27, 2017 08:30 (CEST) Regulatory

Laquinimod

  • The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
  • The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
  • The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
  • Orphan Drug Designation granted for laquinimod for the treatment of Huntington’s disease by the US Food and Drug Administration (FDA)

ANYARA

  • Project proceeding according to plan

Tasquinimod, paquinimod and SILC

  • Out-licensing activities are continuing
  • The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
  • Orphan Drug Designation granted for tasquinimod for the treatment of multiple myeloma by the US Food and Drug Administration (FDA)
  • Product patent for SILC substances granted by the European Patent Office

Financial summary

SEK M Jan.-Mar.   Full-year
2017 2016  2016
Net sales 4.7   3.9   19.0
Operating loss -14.6 -16.1   -55.1
Loss after tax -15.8 -16.8   -59.6
Loss per share, before and after dilution (SEK) -0.16 -0.19 -0.65
Cash and cash equivalents (at close of period) 62.7 76.5   77.7
  • Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:

  Tomas Leanderson, President and CEO
  Tel: +46 (0) 46 19 20 95

 

  Hans Kolam, CFO
  Tel: +46 (0)46 19 20 44

 Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00

The report is also available at www.activebiotech.com.

Active Biotech AB Interim report January – March 2017

—
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire